Perfil
Karen E.
Potts held several regulatory affairs positions in the pharmaceutical industry, including Senior Director-Regulatory Policy at Allergan, Associate Director-Regulatory Affairs at Pfizer, and Director-Regulatory Affairs at Ionis Pharmaceuticals.
She also worked as a Senior Research Scientist in Virology at Agouron Pharmaceuticals and G.D.
Searle LLC.
Potts was Senior Vice President-Regulatory Affairs at MEI Pharma, Inc. and Trius Therapeutics, Inc. She earned a doctorate from Emory University and an undergraduate degree from Smith College.
Antiguos cargos conocidos de Karen Potts.
Empresas | Cargo | Fin |
---|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | General Counsel | 01/09/2013 |
ALLERGAN, INC. | General Counsel | 01/02/2009 |
IONIS PHARMACEUTICALS, INC. | General Counsel | 01/03/2006 |
PFIZER, INC. | General Counsel | 01/07/2003 |
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/10/1999 |
Formación de Karen Potts.
Emory University | Doctorate Degree |
Smith College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
PFIZER, INC. | Health Technology |
IONIS PHARMACEUTICALS, INC. | Health Technology |
MEI PHARMA, INC. | Health Technology |
Empresas privadas | 4 |
---|---|
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Health Technology |
Allergan, Inc.
Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
G.D. Searle LLC |
- Bolsa de valores
- Insiders
- Karen Potts